BioSpace News Archive

Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2022.

Kanna Health Ltd (Kanna Health) - Today, the World Intellectual Property Office has published Kanna Health’s patent application covering the use of KH-001 as a treatment for premature ejaculation, entitled “Methods for delay of ejaculation in human males” (WO/2022/140417).

JustLight, a public benefit corporation, announced today it’s launching clinical trials for its medical device, Sunflower Rx™, which provides smart photobiomodulation (PBM) treatment for Alzheimer’s disease.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has received regulatory approval to begin its first-in-human Phase 1 clinical study of SBI-100 Ophthalmic Emulsion (“SBI-100 OE”) from the Australian Human Research Ethics Committee (“HREC”).

GoodCap Pharmaceuticals Inc. (“GoodCap”), a biopharmaceutical company developing low-dose psychedelic therapies, is pleased to announce publication of its international patent application (PCT/IB2021/059301) (the “Patent”).

Faeth Therapeutics, a cancer metabolism company, today announced the closing of a $47 million Series A round of private financing led by S2G Ventures, bringing total funding to date to $67 million.

An Global Cancer Cachexia Market analysis report comprises of the right information at fingertips which is the key to making faster and more informed decisions.

LiveMetric, a leader in medical wearable technology, today announced the launch of LiveOne, the world’s first 510(k) U.S. Food and Drug Administration (FDA) cleared nano-sensor technology for monitoring blood pressure every 10 seconds.

Benson Hill, Inc., a food tech company unlocking the natural genetic diversity of plants, announced a revised time for its second quarter earnings call and webcast to 8 a.m. Eastern Time from 8:30 a.m. Eastern Time on Monday, Aug. 8, 2022.

Tevogen Bio announced its new Research and Development Center located in Philadelphia’s historic Wanamaker building to further expand the company’s R&D capability allowing expansion of its precision T cell product pipeline.